Bioceltix S.A. (BCX) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Bioceltix S.A. stock PLN 46.51, price PLN 67.00, that is 30.6% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Bioceltix S.A.
BCX · WARExpensive (fair value 31% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 29.70 PLN – 126.80 PLN · fair‑value band 34.88 PLN – 58.14 PLN · the 67.00 PLN price screens above the 46.51 PLN fair value. As of Nov 16, 2026.
Every Wednesday you see whether Bioceltix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use.
Show moreShow less
The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses.
The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Stock analysis
Bioceltix S.A. (BCX) currently trades at 67.00 PLN, while our estimate is 46.51 PLN, 31% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 34.88 PLN (bear) to 58.14 PLN (bull), the price of 67.00 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Bioceltix S.A. reported revenue of 0 PLN in FY2025 versus 0 PLN in FY2021. Reported net income was −15.2M PLN in FY2025.
Key figures
Market cap 371M PLN (≈ $92.5M) Micro · EPS (TTM) −3.47 PLN · Return on equity −39.5% · Return on assets (EBIT) −85.3% (5-year average) · Free cash flow −13.9M PLN · Net cash 68.1M PLN.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, BCX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Bioceltix S.A. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Piotroski F-Score screener with fair value
- Valuation of the Poland market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs BCX |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs BCX |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs BCX |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs BCX |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs BCX |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs BCX |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs BCX |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs BCX |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs BCX |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs BCX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bioceltix S.A. (BCX) overvalued or undervalued?
What is the fair value of BCX?
What is the quality score of BCX?
What is the price target for Bioceltix S.A. (BCX)?
What is the Bioceltix S.A. stock forecast for 2026?
What is the intrinsic value of Bioceltix S.A. (BCX)?
Is Bioceltix S.A. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of BCX?
How much is Bioceltix S.A. worth?
What do the bullish and bearish scenarios say about BCX?
How solid is the balance sheet of Bioceltix S.A. (BCX)?
How far is BCX from its 52-week high?
Which stocks are comparable to Bioceltix S.A.?
Is Bioceltix S.A. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Bioceltix S.A. (BCX)?
What should I pay attention to with Bioceltix S.A. right now?
Key figures of Bioceltix S.A.
How large is the market capitalisation of Bioceltix S.A. (BCX)?
What are the earnings per share of Bioceltix S.A. (BCX)?
What is the return on equity of Bioceltix S.A. (BCX)?
What is the EBIT return on assets of Bioceltix S.A. (BCX)?
How much free cash flow does Bioceltix S.A. (BCX) generate?
How much net cash does Bioceltix S.A. (BCX) hold?
Watch Bioceltix S.A. in the live analysis
One click puts Bioceltix S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.